Nilotinib Viatris (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, a fusion protein that promotes uncontrolled cell growth in CML. This inhibition blocks downstream signaling pathways, leading to reduced proliferation of leukemic cells and promoting apoptosis, thereby restoring more normal blood cell production.

The prescribed dose of Nilotinib Viatris is determined by the treating physician based on the patient’s disease phase, overall health, and concomitant medications. Dosing is individualized and should follow the prescriber’s instructions and local regulatory guidelines.

The safety of nilotinib in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended while on therapy. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib belongs to the second‑generation tyrosine‑kinase inhibitor class and offers higher potency against BCR‑ABL than first‑generation agents such as imatinib. It is often chosen for patients who need deeper molecular responses or who have resistance/intolerance to earlier TKIs, though individual choice depends on clinical factors.

Nilotinib tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Nilotinib Viatris is taken orally, usually twice daily on an empty stomach (at least one hour before or two hours after a meal). The tablets should be swallowed whole with a glass of water; they must not be chewed, crushed, or split unless directed by a healthcare professional.

The most serious risks include QT interval prolongation, which can lead to potentially fatal cardiac arrhythmias, severe liver injury, pancreatitis, and significant reductions in blood cell counts (neutropenia, thrombocytopenia). Patients should be monitored regularly for these events.

Nilotinib is contraindicated in patients with a known hypersensitivity to nilotinib or any of its excipients, and in individuals taking strong CYP3A4 inhibitors or medications that significantly prolong the QT interval. It should also be avoided in patients with uncontrolled cardiac disease or severe hepatic impairment.